Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression analysis products, today announced the launch of its miRCURY™ Exosome Isolation kits for exosome isolation from various biofluids and cell media.
Over the past few years the body of scientific literature has documented the biological importance of exosomes. Exosomes play a key role in cell to cell communication, cell migration, cell differentiation etc. Exosomes contain protein and RNA and may be a preferred target for identification of new biomarkers. However, the isolation of exosomes is challenged by the lack of reproducibility, lack of specificity and tedious work processes. Exiqon’s new miRCURY™ Exosome Isolation Kits address these challenges.
The miRCURY™ Exosome Isolation Kits ensure very high recovery of exosomes in less than two hours and is based on non-toxic reagents. By the use of miRCURY™ Exosome Isolation Kits, exosomes may be isolated from divers sources such as serum, plasma, urine, CSF and cell culture media.
“The miRCURY™ Exosome Isolation Kits consolidate Exiqon as the leading provider of products for analysis of biofluids. With many auxiliary and integrated products Exiqon are able to provide solutions for any RNA biomarker study in biofluids” says Henrik M. Pfundheller, SVP, Sales and Marketing.
The miRCURY™ Exosome Isolation Kits are optimized for use with the miRCURY™ RNA Isolation Kits and the miRCURY LNA™ Universal RT microRNA PCR platform. Exiqon’s PCR offering now includes two new Exosome miRCURY LNA™ Universal RT microRNA qPCR Focus Panels. The focus Panels contain LNA™ enhanced primer sets targeting microRNAs typically found in exosomes from urine and CSF. The primer sets have been thoroughly selected from a combination of literature mining and Exiqon’s internal diagnostic microRNA programs.
Further details about the miRCURY™ Exosome isolation kits and the Exosome microRNA Focus PCR Panel are available at www.exiqon.com/exosome-isolation-kits and www.exiqon.com/exosome-mirna-pcr, respectively.
Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Henrik M. Pfundheller, VP Sales & Marketing, tel. +45 4565 0420 (cell: +45 4090 2106)
Exiqon's products are based on the proprietary LNA™ technology. This technology offers unique advantages for detection of miRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of miRNA research products for miRNA analysis in cells. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to develop new medicines based on miRNA as biological markers. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information about us, please visit www.exiqon.com.